Loading..

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell 2000 Growth Index

2022-06-24 00:00:00

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell 2000 Growth Index

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell Small Cap Comp Growth Index

2022-06-24 00:00:00

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell Small Cap Comp Growth Index

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell 3000 Growth Index

2022-06-24 00:00:00

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell 3000 Growth Index

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell 3000E Growth Index

2022-06-24 00:00:00

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell 3000E Growth Index

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell Microcap Growth Index

2022-06-24 00:00:00

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell Microcap Growth Index

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell 2500 Growth Index

2022-06-24 00:00:00

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell 2500 Growth Index

Mersana Therapeutics, Inc. Presents at 3rd Annual Oncology Innovation Summit: Insights for ASCO & EHA, Jun-02-2022 01:00 PM

2022-05-26 12:00:00

Mersana Therapeutics, Inc. Presents at 3rd Annual Oncology Innovation Summit: Insights for ASCO & EHA, Jun-02-2022 01:00 PM.

Mersana Therapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-10-2022 10:00 AM

2022-05-26 12:00:00

Mersana Therapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-10-2022 10:00 AM. Venue: Marriott Marquis, New York City, New York, United States.

Mersana Therapeutics, Inc. Presents at The JMP Securities Life Sciences Conference 2022, Jun-15-2022 03:00 PM

2022-05-09 14:47:00

Mersana Therapeutics, Inc. Presents at The JMP Securities Life Sciences Conference 2022, Jun-15-2022 03:00 PM. Venue: Lotte New York Palace, 455 Madison Ave., New York City, New York, United States.

Mersana Therapeutics, Inc., Q1 2022 Earnings Call, May 09, 2022

2022-05-02 12:00:00

Mersana Therapeutics, Inc., Q1 2022 Earnings Call, May 09, 2022

Mersana Therapeutics, Inc. to Report Q1, 2022 Results on May 09, 2022

2022-05-02 12:00:00

Mersana Therapeutics, Inc. announced that they will report Q1, 2022 results on May 09, 2022

Mersana Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

2022-04-29 10:08:00

Mersana Therapeutics, Inc., Annual General Meeting, Jun 09, 2022, at 09:00 US Eastern Standard Time. Agenda: To consider directorate reelections; to consider to reelect its auditor for the fiscal year December 31, 2022; and to consider other matters.

Mersana Therapeutics, Inc. - Shareholder/Analyst Call

2022-04-29 10:08:00

AGM

Mersana Therapeutics, Inc. Presents at AACR Annual Meeting 2022, Apr-08-2022 through Apr-14-2022

2022-04-05 12:00:00

Mersana Therapeutics, Inc. Presents at AACR Annual Meeting 2022, Apr-08-2022 through Apr-14-2022. Venue: Ernest N. Morial Convention Center, New Orleans, Louisiana, United States. Presentation Date(s): Apr-11-2022. Apr-12-2022.

Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1660, XMT-2056 and the Immunosynthen Platform at AACR Annual Meeting

2022-04-05 12:00:00

Mersana Therapeutics, Inc. announced that it will present three posters highlighting data for XMT-1660, XMT-2056, and the Immunosynthen ADC platform at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022 to be held in New Orleans, Louisiana from April 8-13, 2022. XMT-1660 is a Dolasynthen ADC targeting B7-H4, a target selectively expressed on tumors in areas of high unmet medical need, including breast, endometrial, ovarian and other cancers. The data show that a single dose of XMT-1660 has anti-tumor activity in both triple-negative breast cancer (TNBC) and estrogen receptor (ER)-positive breast cancer xenograph models. Higher B7-H4 expression is associated with greater anti-tumor activity of XMT-1660 in preclinical studies. Mersana expects a Phase 1 clinical trial for XMT-1660 to start in mid-2022. XMT-2056, Mersana’s first Immunosynthen STING-agonist ADC, targets a novel epitope of HER2, and is designed to offer a differentiated and complementary therapeutic approach to the treatment of HER2-expressing tumors. The preclinical data presented show that XMT-2056 demonstrates robust anti-tumor activity as a monotherapy in both HER2-high and HER2-low expressing models. XMT-2056’s complementary mechanism of action results in increased efficacy in combination with trastuzumab, pertuzumab, anti-PD-1, or trastuzumab deruxtecan in preclinical studies. Mersana expects to initiate a Phase 1 clinical trial of XMT-2056 in mid-2022. Immunosynthen is Mersana’s immunostimulatory ADC platform designed to take ADCs beyond traditional cytotoxic drugs to targeted stimulation of the innate immune system. Data show that anti-tumor activity of Immunosynthen STING-agonist ADCs involves the targeted activation of the STING pathway in an antigen binding-dependent manner in both tumor-resident immune cells and in tumor cells. In addition to delivery to the tumor cell via antigen binding and internalization, data from multiple models demonstrate Fc?-R1 is the major receptor that mediates delivery to a specific population of myeloid cells resident in primary human tumors, eliciting potent anti-tumor responses in preclinical studies.

Cowen Inc., 3rd Annual Oncology Innovation Summit: Insights for ASCO & EHA, Jun 02, 2022

2022-03-28 15:12:00

Cowen Inc., 3rd Annual Oncology Innovation Summit: Insights for ASCO & EHA, Jun 02, 2022.

JMP Securities LLC, the JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022

2022-02-16 16:45:00

JMP Securities LLC, The JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022. Venue: Lotte New York Palace, 455 Madison Ave., New York City, New York, United States.

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Mersana Therapeutics, Inc. Presents at SLAS 2022 International Conference and Exhibition, Feb-08-2022 04:00 PM

2022-02-05 10:28:00

Mersana Therapeutics, Inc. Presents at SLAS 2022 International Conference and Exhibition, Feb-08-2022 04:00 PM. Venue: Boston Convention and Exhibition Center, Boston, Massachusetts, United States. Speakers: Kalli Catcott, Naniye Malli.

Mersana Therapeutics, Inc. Announces Research Collaboration and License Agreement with Janssen Biotech, Inc. to Advance Novel Antibody-Drug Conjugates

2022-02-03 12:00:00

Mersana Therapeutics, Inc. announced a research collaboration and license agreement with Janssen Biotech, Inc. to discover novel ADCs for three targets. The agreement was facilitated by Johnson & Johnson Innovation. Under the terms of the agreement, Janssen will provide proprietary antibodies for three targets. Mersana will apply its expertise and its proprietary Dolasynthen platform to discover novel ADC product candidates. Mersana may leverage Synaffix’s GlycoConnectTM technology as its preferred site-specific ADC bioconjugation technology. Mersana will collaborate with Janssen on target candidates during preclinical development, with Janssen being solely responsible for clinical development and commercialization. Mersana will receive an upfront payment of $40 million. Mersana is eligible to receive reimbursement of certain costs as well as more than $1 billion in potential milestone payments, plus mid-single-digit to low double-digit percentage royalties on worldwide net sales of ADCs against the selected targets.

American Association For Cancer Research, AACR Annual Meeting 2022, Apr 08, 2022 through Apr 14, 2022

2022-01-13 18:45:00

American Association For Cancer Research, AACR Annual Meeting 2022, Apr 08, 2022 through Apr 14, 2022. Venue: Ernest N. Morial Convention Center, New Orleans, Louisiana, United States.

Society for Laboratory Automation & Screening, SLAS 2022 International Conference and Exhibition, Feb 05, 2022 through Feb 09, 2022

2021-12-28 18:17:00

Society for Laboratory Automation & Screening, SLAS 2022 International Conference and Exhibition, Feb 05, 2022 through Feb 09, 2022. Venue: Boston Convention and Exhibition Center, Boston, Massachusetts, United States.

Mersana Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 02:40 PM

2021-11-23 13:00:00

Mersana Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 02:40 PM.

Mersana Therapeutics, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-17-2021 03:20 PM

2021-11-10 13:02:00

Mersana Therapeutics, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-17-2021 03:20 PM. Venue: New York, New York, United States. Speakers: Anna Protopapas, President and Chief Executive Officer.

Mersana Therapeutics, Inc. has filed a Shelf Registration in the amount of $300 million.

2021-11-09 00:00:00

Mersana Therapeutics, Inc. has filed a Shelf Registration in the amount of $300 million. Security Name: Common Stock Security Name: Preferred Stock Security Name: Warrants Security Name: Units Transaction Features: Omnibus/Universal Shelf Registration

Mersana Therapeutics, Inc., Q3 2021 Earnings Call, Nov 09, 2021

2021-11-02 12:00:00

Mersana Therapeutics, Inc., Q3 2021 Earnings Call, Nov 09, 2021

Mersana Therapeutics, Inc. Enters into A Loan and Security Agreement

2021-10-29 21:25:00

On October 29, 2021 Mersana Therapeutics, Inc. entered into a Loan and Security Agreement (the Loan Agreement") by and among the Company, Oxford Finance LLC, in its capacity as collateral agent (in such capacity, the Agent") and a lender, and Silicon Valley Bank as a lender (collectively, the Lenders"), pursuant to which term loans of up to an aggregate principal amount of $100.0 million is available to the Company, consisting of (i) a tranche A term loan in the aggregate principal amount of up to $60.0 million available at any time on or prior to December 31, 2022 at the option of the Company, $25.0 million of which was disbursed on the Closing Date and utilized, in part, to repay existing indebtedness of the Company; (ii) a contingent tranche B term loan in the aggregate principal amount of $10.0 million available to the Company at any time on or prior to December 31, 2022, within 90 days of the Company having both (x) enrolled and dosed the first patient in a Phase I trial for XMT-2056 and (y) enrolled and dosed the first patient in a Phase I trial for XMT-1660, so long as the UpRi UPLIFT cohort intended to support a submission of a Biologics License Application is ongoing; (iii) a contingent tranche C term loan in the aggregate principal amount of $10.0 million available to the Company at any time on or prior to June 30, 2023, within 90 days of the Company having received positive data from the UpRi UPLIFT registrational trial sufficient to support a Biologics License Application; and (iv) a contingent tranche D term loan in the aggregate principal amount of $20.0 million available at any time on or prior to November 1, 2024 (extended to November 1, 2025 if the tranche C term loan milestone is achieved), which is available in the sole discretion of the Lenders, subject, in each case of the foregoing, to certain other terms and conditions.

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.

Mersana Therapeutics, Inc. Appoints Mohan Bala as SVP, Strategic Product Planning & Program Leadership

2021-10-25 12:00:00

Mersana Therapeutics, Inc. announced the appointment of Mohan Bala as SVP, Strategic Product Planning & Program Leadership, effective October 25, 2021. Dr. Bala will assume strategic product planning responsibilities from Brian DeSchuytner who has been named SVP and Chief Financial Officer. Mr. DeSchuytner will continue to lead finance, business development, corporate strategy and investor relations and remain Mersana’s principal financial officer. Mohan Bala, Ph.D., was most recently Chief Operating Officer at Constellation Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics to address patients with cancers associated with abnormal gene expression. While at Constellation, Dr. Bala was responsible for overall asset strategy and program management. Prior to joining Constellation, Dr. Bala served as VP, Development Program Lead at TESARO, where he led cross-functional teams to advance two products to Phase 2 and one product to regulatory filing. He has been involved in multiple successful BLA and MAAs, including the filing of a companion diagnostic. Earlier in his career, Dr. Bala held senior leadership roles at Sanofi, GlaxoSmithKline and Centocor.

Mersana Therapeutics, Inc. Presents at Antibody Engineering & Therapeutics US, Dec-16-2021 10:30 AM

2021-10-06 12:38:00

Mersana Therapeutics, Inc. Presents at Antibody Engineering & Therapeutics US, Dec-16-2021 10:30 AM. Venue: Marriott Marquis San Diego, San Diego, California, United States. Speakers: Timothy B. Lowinger, Chief Science & Technology Officer.

Mersana Therapeutics to Announce Target and Present New Preclinical Data for Xmt-2056 At the Aacr-Nci-Eortc Virtual International Conference on Molecular Targets and Cancer Therapeutics

2021-09-30 12:00:00

Mersana Therapeutics, Inc. announced that it will disclose the target and present new preclinical data for XMT-2056, its first Immunosynthen STING-agonist ADC candidate, in a plenary session at the upcoming AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.

Mersana Therapeutics, Inc. Presents at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, Oct-07-2021 12:50 PM

2021-09-30 12:00:00

Mersana Therapeutics, Inc. Presents at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, Oct-07-2021 12:50 PM. Speakers: Timothy B. Lowinger, Chief Science & Technology Officer.

Mersana Therapeutics, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-15-2021 01:15 PM

2021-09-07 16:42:00

Mersana Therapeutics, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-15-2021 01:15 PM. Venue: New Windsor, United States.

Mersana Therapeutics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-28-2021 04:00 PM

2021-09-07 12:00:00

Mersana Therapeutics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-28-2021 04:00 PM. Venue: New York, United States.

Mersana Therapeutics, Inc. - Special Call

2021-09-01 12:00:00

To discuss the progress of its clinical development strategy for upifitamab rilsodotin (UpRi) and report updated interim data from the ovarian cancer expansion cohort of the UpRi Phase 1 study. Enrollment in the expansion cohort is complete with 97 patients evaluable for safety and tolerability, of which 75 are RECIST-evaluable at this interim analysis

Mersana Therapeutics, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 08:30 AM

2021-08-26 17:20:00

Mersana Therapeutics, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 08:30 AM. Speakers: Anna Protopapas, President, CEO & Director.

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Mersana Therapeutics, Inc. Announces Executive Changes

2021-08-16 12:00:00

Mersana Therapeutics, Inc. announced the appointment of Tushar Misra, Ph.D., as Chief Manufacturing Officer, effective August 16, 2021. Dr. Misra replaces Michael Kaufman, Ph.D., who is retiring from Mersana after more than five years with the Company. Dr. Kaufman will remain at Mersana to ensure a smooth transition until September 10, 2021. Tushar Misra, Ph.D., was most recently EVP, Head of Technical Development & Manufacturing at Laronde. While at Laronde, he led the process development and support team for end-to-end manufacturing for preclinical and clinical research. Before that, he was SVP, Technical Operations at Wave Life Sciences. Prior to Wave Life Sciences, Dr. Misra worked at Takeda Pharmaceuticals in several positions of increasing seniority, most recently as VP & Head, Global Oncology and Biologics Operations. While at Takeda, he built world-wide manufacturing and supply chain infrastructure for the company’s biologic and oncology commercial products including ADCETRIS® (brentuximab vedotin) and ENTYVIO (vedolizumab). Earlier in his career, he held senior executive leadership roles in Chemistry and Pharmaceutical Sciences at Sunovion Pharmaceuticals, Inc. (previously Sepracor, Inc.).

American Association For Cancer Research, National Cancer Institute, The European Organisation For Research and Treatment of Cancer (eortc), 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, Oct 07, 2021 through Oct 11, 2021

2021-08-11 12:00:00

American Association For Cancer Research, National Cancer Institute, The European Organisation For Research and Treatment of Cancer (eortc), 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, Oct 07, 2021 through Oct 11, 2021.

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021

2021-08-10 13:03:00

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.

Mersana Therapeutics, Inc. Presents at BTIG Virtual Biotechnology Conference, Aug-10-2021 09:00 AM

2021-08-04 12:33:00

Mersana Therapeutics, Inc. Presents at BTIG Virtual Biotechnology Conference, Aug-10-2021 09:00 AM. Speakers: Anna Protopapas, President, CEO & Director, Arvin Yang, Senior VP & Chief Medical Officer, Brian C. DeSchuytner, Senior Vice President of Finance & Product Strategy, James Salierno, Investor Relations, Sarah Carmody, Executive Director of Investor Relations & Corporate Communications, Timothy B. Lowinger, Chief Science & Technology Officer.

Mersana Therapeutics, Inc. Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-11-2021 02:20 PM

2021-08-04 12:00:00

Mersana Therapeutics, Inc. Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-11-2021 02:20 PM. Speakers: Timothy B. Lowinger, Chief Science & Technology Officer.

Mersana Therapeutics, Inc., Q2 2021 Earnings Call, Aug 06, 2021

2021-07-30 12:00:00

Mersana Therapeutics, Inc., Q2 2021 Earnings Call, Aug 06, 2021

Mersana Therapeutics Announces Initiation of the UPGRADE Phase 1 Platinum Combination Cohort for UpRi in Platinum-Sensitive Ovarian Cancer

2021-07-28 12:00:00

Mersana Therapeutics, Inc. announced the initiation of patient dosing in UPGRADE, a Phase 1 combination dose escalation umbrella study to evaluate the safety and efficacy of upifitamab rilsodotin (UpRi, previously XMT-1536) in combination with other ovarian cancer therapies. The initial arm of this umbrella study is evaluating carboplatin in combination with UpRi followed by continuation of UpRi monotherapy in patients with platinum-sensitive ovarian cancer. The UPGRADE Phase 1, open-label, dose-escalation portion of the study will determine the maximum tolerated dose (MTD) and safety and tolerability of a once-every-four-week (Q4W) administration of UpRi in combination with carboplatin for six cycles followed by continuation of UpRi monotherapy in patients with platinum-sensitive high-grade serous ovarian cancer following 1-2 prior platinum-based regimens. Patients will not be preselected for NaPi2b expression; however, archival or fresh tissue will be required for retrospective assessment of expression. Upon completion of the dose-escalation portion of the study, the Company plans to initiate the expansion portion to assess both tolerability and efficacy and inform the further development of UpRi in a broader and earlier-line patient population.

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021

2021-07-08 08:44:00

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New York, United States.

BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021

2021-07-01 10:09:00

BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021.

Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021

2021-06-29 20:28:00

Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021.